# US 2023/0265128 A1 · Stabilised viral fusion proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265128 A1
- Document ID: US20230265128A1
- Status: Published application
- Kind: A1
- Application number: 17/910,598
- Filed: 2021-03-12
- Published: 2023-08-24
- Earliest claimed: 2020-03-12
- Assignees: Oxford University Innovation Limited
- Applicants: Oxford University Innovation Limited
- Inventors: Alexander DOUGLAS; Sofiya FEDOSYUK
- Web page: https://patentgrep.com/patent/US20230265128A1

## CPC

- C07K 14/005: from viruses
- A61K 39/12: Viral antigens
- C12N 15/86: Viral vectors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2710/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/16222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/16622: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/16634: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2760/20122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/20134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/20222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/20234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to stabilised pre-fusion conformation Class III fusion proteins. The inve ntion also provides vaccine compositions for immunising a subject against viral infections.

## Claims

### Claim 1

A stable pre-fusion Class III fusion protein, or an immunogenic fragment thereof, comprising one or more mutations that prevent formation of the central extended helix in the post-fusion conformation trimerisation interface.

### Claim 2 (depends on 1)

The protein or immunogenic fragment thereof of claim 1, wherein said one or more mutation that prevents the formation of the central extended helix is a mutation that prevents extension of the pre-fusion conformation central helix into the post-fusion central extended helix.

### Claim 3 (depends on 1, 2)

The protein or immunogenic fragment thereof, of claim 1 or 2, wherein said central extended helix in the post-fusion conformation trimerisation interface corresponds to or aligns with:
(a) the extended helix C in rabies virus glycoprotein (RVG);
(b) helix F of the trimerisation domain of vesicular stomatitis virus glycoprotein (VSVG); and/or
(c) helix alpha-C of the trimerisation domain of Epstein-Barr virus glycoprotein B (EBV gB).

### Claim 4

The protein or immunogenic fragment thereof of any one of the preceding claims, wherein said central extended helix in the post-fusion conformation trimerisation interface is defined as extending, at its N-terminal end, up to the 32nd amino acid residue N-terminal to the conserved cysteine residue of the Class III fusion protein and, at its C-terminal end, up to the 16th amino acid residue C-terminal to the conserved cysteine of the Class III fusion protein; wherein optionally the conserved cysteine residue corresponds to or aligns with:
(a) amino acid residue 283 of the RVG sequence according to SEQ ID NO: 3;
(b) amino acid residue 284 of the VSVG sequence according to SEQ ID NO: 5;
(c) amino acid residue 484 of the EBV gB sequence according to SEQ ID NO: 6;
(d) amino acid residue 507 of the cytomegalovirus glycoprotein B (CMV gB) sequence according to SEQ ID NO: 8; and/or
(e) amino acid residue 529 of the herpes simplex virus glycoprotein B (HSV-1 gB) sequence according to SEQ ID NO: 10.
(f) amino acid residue 526 of the herpes simplex virus glycoprotein B (HSV-2 gB) sequence according to SEQ ID NO: 32.

### Claim 5

The protein or immunogenic fragment thereof of any one of the preceding claims, wherein said central extended helix of the post-fusion conformation trimerisation interface corresponds to, or aligns with amino acid residues:
(a) 262 to 293 of the RVG sequence of SEQ ID NO: 3;
(b) 263 to 294 of the VSVG sequence of SEQ ID NO: 5;
(c) 458 to 500 of the EBV gB sequence of SEQ ID NO: 6;
(d) 481 to 520 of the CMV gB sequence of SEQ ID NO: 8; and/or
(e) 503 to 545 of the HSV-1 gB sequence of SEQ ID NO: 10.

### Claim 6

The protein or immunogenic fragment thereof of any one of the preceding claims, wherein the Class III fusion protein is a:
(a) RVG;
(b) VSVG; or
(c) herpesvirus glycoprotein B, wherein optionally said herpesvirus is selected from a cytomegalovirus, Epstein- Barr virus, herpes simplex virus-1 and/or herpes simplex virus-2.

### Claim 7

The protein or immunogenic fragment thereof of any one of the preceding claims, wherein said one or more mutation is an amino acid substitution.

### Claim 8

The protein or immunogenic fragment thereof of any one of the preceding claims, wherein said amino acid substitution is a non-conservative amino acid substitution.

### Claim 9

The protein or immunogenic fragment thereof of any one of the preceding claims, wherein said one or more mutation is:
(a) a helix-disrupting mutation and said amino acid substitution is a substitution by proline; and/or
(b) an amino acid substitution by an amino acid with increased hydrophobicity compared with the amino acid being substituted, wherein said amino acid substitution is independently selected from a substitution by leucine, alanine, isoleucine or valine.

### Claim 10

The protein or immunogenic fragment thereof of any one of the preceding claims, wherein said one or more mutation is at an amino acid corresponding to, or aligning with, position 270, 271, 272 and/or 273 of the RVG sequence of SEQ ID NO: 3.

### Claim 11

The protein or immunogenic fragment thereof of any one of the preceding claims, wherein the amino acid corresponding to position:
(a) 270 of the RVG sequence of SEQ ID NO: 3 is substituted by proline;
(b) 271 of the RVG sequence of SEQ ID NO: 3 is substituted by proline;
(c) 272 of the RVG sequence of SEQ ID NO: 3 is substituted by proline; and/or
(d) 273 of the RVG sequence of SEQ ID NO: 3 is substituted by proline.

### Claim 12

The protein or immunogenic fragment thereof of any one of the preceding claims, wherein the Class III fusion protein is a RVG and wherein said protein comprises one or more amino acid substitutions selected from H270P, L271P, V272P and/or V273P.

### Claim 13

The protein or immunogenic fragment thereof of any one of the preceding claims, wherein the protein or immunogenic fragment thereof is RVG comprising an amino acid sequence selected from SEQ ID NOs: 11, 12, 13 or 14.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The protein or immunogenic fragment thereof of any one of claims 1 to 9, wherein said one or more mutation is at an amino acid corresponding to, or aligning with, position 516, 517, 518 and/or 519 of the HSV gB sequence of SEQ ID NO: 10.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 14)

The protein or immunogenic fragment thereof of any one of claims 1 to 9 or 14, wherein the amino acid corresponding to position:
(a) 516 of the HSV gB sequence of SEQ ID NO: 10 is substituted by proline;
(b) 517 of the HSV gB sequence of SEQ ID NO: 10 is substituted by proline;
(c) 518 of the HSV gB sequence of SEQ ID NO: 10 is substituted by proline; and/or
(d) 519 of the HSV gB sequence of SEQ ID NO: 10 is substituted by proline.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 14, 15)

The protein or immunogenic fragment thereof of any one of claims 1 to 9, 14 or 15, wherein the Class III fusion protein is an HSV gB and wherein said protein comprises one or more amino acid substitutions selected from H516P, V517P, N518P and/or D519P.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 14, 15, 16)

The protein or immunogenic fragment thereof of any one of claims 1 to 9 or 14 to 16, wherein the protein or immunogenic fragment thereof is HSV gB comprising an amino acid sequence selected from SEQ ID NOs: 27, 28, 29 or 30.

### Claim 18

A stable pre-fusion Class III fusion protein, or an immunogenic fragment thereof, comprising:
(a) one or more non-conservative amino acid substitutions within its pre-fusion conformation central helix; and/or
(b) one or more non-conservative amino acid substitutions within amino acid residues corresponding to or aligning with amino acid residues: (i) 262 to 293 of the RVG sequence of SEQ ID NO: 3; (ii) 263 to 294 of the VSVG sequence of SEQ ID NO: 5; (iii) 458 to 500 of the EBV gB sequence of SEQ ID NO: 6; (iv) 481 to 520 of the CMV gB sequence of SEQ ID NO: 8; and/or (v) 503 to 545 of the HSV-1 gB sequence of SEQ ID NO: 10;
wherein preferably the one or more non-conservative amino acid substitution is substitution by proline.

### Claim 19

The protein or immunogenic fragment thereof of any one of the preceding claims, which further comprises one or more additional mutations in a region other than the central extended helix of the post-fusion conformation trimerisation interface.

### Claim 20 (depends on 19)

The protein or immunogenic fragment thereof of claim 19, wherein said one more additional mutation is a mutation in an amino acid corresponding to or aligning with position:
(a) 261 of the RVG sequence of SEQ ID NO: 3;
(b) 262 of the VSVG sequence of SEQ ID NO: 5;
(c) 462 of the EBV gB sequence of SEQ ID NO: 6;
(d) 485 of the CMV gB sequence of SEQ ID NO: 8; and/or
(e) 507 of the HSV gB sequence of SEQ ID NO: 10;
wherein optionally said amino acid mutation is an amino acid substitution by an amino acid with increased hydrophobicity compared to the amino acid being substituted.

### Claim 21

The protein or immunogenic fragment thereof of any one of the preceding claims, which induces neutralising antibodies against one or more epitope of the pre-fusion Class III fusion protein.

### Claim 22 (depends on 21)

The protein or immunogenic fragment thereof of claim 21, which induces neutralising antibodies against (i) antigenic site I; (ii) antigenic site II; and/or (iii) antigenic site III.

### Claim 23

The protein or immunogenic fragment thereof of any one of the preceding claims, for use in a vaccine.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A polynucleotide molecule encoding a protein as defined in any one of claims 1 to 22.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 24)

A viral vector, DNA vector and/or RNA vector:
(a) comprising a polynucleotide as defined in claim 24; and/or
(b) encoding a protein or immunogenic fragment thereof as defined in any one of claims 1 to 22.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A virus-like particle, comprising a protein as defined in any one of claims 1 to 22.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 24, 25, 26)

A vaccine composition, comprising a protein as defined in any one of claims 1 to 22, a polynucleotide molecule as defined in claim 24, a viral vector and/or DNA vector and/or RNA vector as defined in claim 25, and/or a virus-like particle as defined in claim 26, and optionally a pharmaceutically acceptable excipient.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

An antibody, or binding fragment thereof, that specifically binds to the protein or immunogenic fragment thereof as defined in any one of claims 1 to 22.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 24, 25, 26, 27, 28)

The protein of any one of claims 1 to 22, and/or the vaccine composition of claim 27, and/or the polynucleotide of claim 24, and/or the viral vector and/or DNA vector and/or RNA vector of claim 25 and/or the virus-like particle of claim 26 and/or the antibody of claim 28, for use in a method of immunising a subject against a viral infection.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 24, 25, 26, 27, 28)

Use of the protein of any one of claims 1 to 22, and/or the vaccine composition of claim 27, and/or the polynucleotide of claim 24, and/or the viral vector and/or DNA vector and/or RNA vector of claim 25, and/or the virus-like particle of claim 26, and/or the antibody of claim 28, in the manufacture of a medicament for the immunisation of a subject against a viral infection.

### Claim 31 (depends on 29, 30)

The protein, vaccine composition, polynucleotide, viral vector, DNA vector, RNA vector, virus-like particle and/or antibody for use according to claim 29; or the use of the protein, vaccine composition, polynucleotide, viral vector, DNA vector, RNA vector, virus-like particle and/or antibody according to claim 30; wherein said subject is a mammalian subject, preferably a human subject.

### Claim 32 (depends on 29, 30, 31)

The protein, vaccine composition, polynucleotide, viral vector, DNA vector, RNA vector, virus-like particle and/or antibody for use according to claim 29 or 31; or the use of the protein, vaccine composition, polynucleotide, viral vector, DNA vector, RNA vector, virus-like particle and/or antibody according to claim 30 or 31; wherein said viral infection is a rhabdovirus infection or a herpesvirus infection.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

Use of the protein of any one of claims 1 to 22 for the generation of an antibody, or binding fragment thereof, specific to an epitope of a pre-fusion conformation Class III fusion protein.
